May 2021

— Phase 3 Clinical Study of PL9643 in Patients with Dry Eye Disease Planned for Second Half Calendar 2021 — Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Planned for Second Half Calendar 2021 — Vyleesi Gross Product Sales Up 89%, Net Revenue Up 154%, Prescriptions Increased 24% Compared to Prior Quarter …

Palatin Reports Financial Results for the Third Fiscal Quarter of 2021 and Provides Corporate Update Read More »

Primary focus on PL9643 – Phase 3 Clinical Study in Patients with Dry Eye Disease Planned for Second Half Calendar 2021 Webinar on Friday, May 21st at 10:00 am ET May 14, 2021, 07:30 ET CRANBURY, N.J., May 14, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on …

Palatin Hosting Key Opinion Leader Webinar in Role of Melanocortin Agonists in Inflammation and the Treatment of Ocular Indications Read More »

May 13, 2021, 07:30 ET CRANBURY, N.J., May 13, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2021 operating results on Monday, May 17, 2021 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive …

Palatin to Report Third Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on May 17, 2021 Read More »

May 04, 2021, 07:30 ET CRANBURY, N.J., May 4, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that the United States Patent and Trademark Office (USPTO) issued Notices of Final Determination and Requirement for …

Palatin Announces U.S. Patent Term Extension for Vyleesi® (bremelanotide injection) Read More »